[{"id":"64ec7fee-f0ad-4556-bc3c-857c74e02812","acronym":"","url":"https://clinicaltrials.gov/study/NCT04145115","created_at":"2021-07-05T17:26:08.613Z","updated_at":"2025-02-25T14:07:33.392Z","phase":"Phase 2","brief_title":"A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden","source_id_and_acronym":"NCT04145115","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX","pipe":" | ","alterations":" TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type","tags":["EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 37","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2025-02-17"},{"id":"242a6457-aef1-4b8b-890a-953bd32e515a","acronym":"SAVANNAH","url":"https://clinicaltrials.gov/study/NCT03778229","created_at":"2021-01-18T18:41:19.683Z","updated_at":"2025-02-25T15:34:16.664Z","phase":"Phase 2","brief_title":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","source_id_and_acronym":"NCT03778229 - SAVANNAH","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR amplification • MET overexpression","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR amplification • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Orpathys (savolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 367","initiation":"Initiation: 01/09/2019","start_date":" 01/09/2019","primary_txt":" Primary completion: 08/23/2024","primary_completion_date":" 08/23/2024","study_txt":" Completion: 05/28/2025","study_completion_date":" 05/28/2025","last_update_posted":"2025-02-10"},{"id":"2e5ccca8-120c-4e72-b9c4-3d96418121c2","acronym":"NCI-2018-01218","url":"https://clinicaltrials.gov/study/NCT03065387","created_at":"2021-01-18T15:06:02.917Z","updated_at":"2025-02-25T15:25:34.097Z","phase":"Phase 1","brief_title":"Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation","source_id_and_acronym":"NCT03065387 - NCI-2018-01218","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • KRAS • ERBB3 • ERBB4","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification","tags":["HER-2 • KRAS • ERBB3 • ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Ibrance (palbociclib) • everolimus • Nerlynx (neratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 10/31/2017","start_date":" 10/31/2017","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-10"},{"id":"fb005881-4dad-4aee-8405-d3b9ee7b7d75","acronym":"","url":"https://clinicaltrials.gov/study/NCT05463848","created_at":"2022-07-19T15:55:14.520Z","updated_at":"2025-02-25T16:17:57.365Z","phase":"Phase 2","brief_title":"Surgical Pembro +/- Olaparib W TMZ for RGBM","source_id_and_acronym":"NCT05463848","lead_sponsor":"L. Nicolas Gonzalez Castro, MD, PhD","biomarkers":" EGFR • TERT","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • IDH wild-type","tags":["EGFR • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 10/21/2022","start_date":" 10/21/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-02-06"},{"id":"3c19bae1-0bb5-4981-9c9a-f622527c42f9","acronym":"MCLA-158-CL01","url":"https://clinicaltrials.gov/study/NCT03526835","created_at":"2023-02-28T17:01:26.541Z","updated_at":"2025-02-25T17:36:01.506Z","phase":"Phase 1/2","brief_title":"A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03526835 - MCLA-158-CL01","lead_sponsor":"Merus N.V.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • petosemtamab (MCLA-158)"],"overall_status":"Recruiting","enrollment":" Enrollment 523","initiation":"Initiation: 05/02/2018","start_date":" 05/02/2018","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-01-29"},{"id":"d78d7b46-d2cc-485a-8c04-81f9d73189d4","acronym":"KEYNOTE-E28","url":"https://clinicaltrials.gov/study/NCT04429542","created_at":"2021-01-18T21:20:02.191Z","updated_at":"2025-02-25T16:10:23.024Z","phase":"Phase 1","brief_title":"Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors","source_id_and_acronym":"NCT04429542 - KEYNOTE-E28","lead_sponsor":"Bicara Therapeutics","biomarkers":" PD-L1","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • RAS wild-type • KRAS G12 • KRAS G13 • EGFR negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • RAS wild-type • KRAS G12 • KRAS G13 • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ficerafusp alfa (BCA101)"],"overall_status":"Recruiting","enrollment":" Enrollment 292","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-01-27"},{"id":"eca89281-345b-4922-b035-d805f889120c","acronym":"NCI-2018-02010","url":"https://clinicaltrials.gov/study/NCT03732352","created_at":"2021-01-18T18:16:58.787Z","updated_at":"2025-02-25T15:08:03.210Z","phase":"Phase 2","brief_title":"18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma","source_id_and_acronym":"NCT03732352 - NCI-2018-02010","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" EGFR • TP53","pipe":" | ","alterations":" TP53 mutation • EGFR mutation • EGFR amplification","tags":["EGFR • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • EGFR mutation • EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 11/28/2018","start_date":" 11/28/2018","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 01/31/2024","study_completion_date":" 01/31/2024","last_update_posted":"2024-11-12"},{"id":"eb5c9ee3-620e-48d0-bab8-f8f2914ede1d","acronym":"NRG-BN010","url":"https://clinicaltrials.gov/study/NCT04729959","created_at":"2021-03-09T19:55:01.650Z","updated_at":"2024-07-02T16:34:27.180Z","phase":"Phase 2","brief_title":"Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma","source_id_and_acronym":"NCT04729959 - NRG-BN010","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • MGMT • TERT","pipe":" | ","alterations":" EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["EGFR • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Actemra IV (tocilizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 03/11/2022","start_date":" 03/11/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-11"},{"id":"87923196-97d9-4e54-a07f-3d2558fab429","acronym":"","url":"https://clinicaltrials.gov/study/NCT02101905","created_at":"2021-01-18T09:41:49.492Z","updated_at":"2024-07-02T16:35:07.246Z","phase":"Phase 1","brief_title":"Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma","source_id_and_acronym":"NCT02101905","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 03/13/2014","start_date":" 03/13/2014","primary_txt":" Primary completion: 10/19/2021","primary_completion_date":" 10/19/2021","study_txt":" Completion: 10/19/2024","study_completion_date":" 10/19/2024","last_update_posted":"2024-04-29"},{"id":"8fd31dd0-c717-4033-9f44-afbf209f365e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04225039","created_at":"2021-03-09T19:53:36.498Z","updated_at":"2024-07-02T16:35:12.728Z","phase":"Phase 2","brief_title":"Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma","source_id_and_acronym":"NCT04225039","lead_sponsor":"University of Pennsylvania","biomarkers":" MGMT • TERT","pipe":" | ","alterations":" EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • ragifilimab (INCAGN1876)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 06/23/2020","start_date":" 06/23/2020","primary_txt":" Primary completion: 09/08/2022","primary_completion_date":" 09/08/2022","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-26"},{"id":"50f8b205-06c7-4e3e-b459-1ebbfce2f273","acronym":"","url":"https://clinicaltrials.gov/study/NCT04910022","created_at":"2021-06-02T20:57:18.421Z","updated_at":"2024-07-02T16:35:14.620Z","phase":"Phase 1/2","brief_title":"Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma","source_id_and_acronym":"NCT04910022","lead_sponsor":"Nerviano Medical Sciences","biomarkers":" EGFR • IDH1 • IDH2 • MGMT • TERT","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • MGMT promoter methylation • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["EGFR • IDH1 • IDH2 • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • MGMT promoter methylation • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • lomustine • itareparib (NMS-293)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-03-15"},{"id":"bc1648bd-c73f-49a2-a8f6-094d16cc301b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05660369","created_at":"2022-12-21T14:58:50.595Z","updated_at":"2024-07-02T16:35:14.877Z","phase":"Phase 1","brief_title":"CARv3-TEAM-E T Cells in Glioblastoma","source_id_and_acronym":"NCT05660369","lead_sponsor":"Marcela V. Maus, M.D.,Ph.D.","biomarkers":" MGMT","pipe":" | ","alterations":" EGFR amplification • EGFRvIII mutation","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • EGFRvIII mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CARv3-TEAM-E T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 03/22/2023","start_date":" 03/22/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-03-13"},{"id":"a716c9c6-6239-4e8b-853c-86fb57b7bc7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05117931","created_at":"2021-11-11T12:53:37.831Z","updated_at":"2024-07-02T16:35:16.106Z","phase":"Phase 2","brief_title":"A Study of Amivantamab in People With Esophagogastric Cancer","source_id_and_acronym":"NCT05117931","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" MET amplification • EGFR amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 12/02/2021","start_date":" 12/02/2021","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-03-06"},{"id":"aebfc79a-06bb-47ab-a81d-a5954af2fab2","acronym":"PATHWAyS","url":"https://clinicaltrials.gov/study/NCT05900908","created_at":"2023-06-13T17:07:56.192Z","updated_at":"2024-07-02T16:35:19.451Z","phase":"Phase 4","brief_title":"Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy","source_id_and_acronym":"NCT05900908 - PATHWAyS","lead_sponsor":"GT Medical Technologies, Inc.","biomarkers":" EGFR • MGMT • TERT","pipe":" | ","alterations":" EGFR amplification • TERT mutation • IDH wild-type","tags":["EGFR • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • TERT mutation • IDH wild-type"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-02-14"},{"id":"80508af6-7ecc-4d80-9db9-bae1a12b6cde","acronym":"","url":"https://clinicaltrials.gov/study/NCT05168423","created_at":"2021-12-23T16:53:41.350Z","updated_at":"2024-07-02T16:35:20.694Z","phase":"Phase 1","brief_title":"CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM","source_id_and_acronym":"NCT05168423","lead_sponsor":"University of Pennsylvania","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification • EGFR wild-type • IDH wild-type","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • EGFR wild-type • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TmEGFR/IL13Rα2 01 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 02/24/2023","start_date":" 02/24/2023","primary_txt":" Primary completion: 12/19/2024","primary_completion_date":" 12/19/2024","study_txt":" Completion: 12/19/2039","study_completion_date":" 12/19/2039","last_update_posted":"2024-02-06"},{"id":"0b1a6a31-b42a-439f-983a-b576150910a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05326464","created_at":"2022-04-13T11:55:14.092Z","updated_at":"2024-07-02T16:35:24.087Z","phase":"Phase 3","brief_title":"Tofacitinib in Recurrent GBM Patients","source_id_and_acronym":"NCT05326464","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" EGFR • MGMT","pipe":" | ","alterations":" EGFR amplification • IDH wild-type","tags":["EGFR • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tofacitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/07/2022","start_date":" 10/07/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-01-09"},{"id":"fe9a8c97-4137-4e63-9045-01b237294fe6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04629209","created_at":"2021-01-19T20:36:09.384Z","updated_at":"2024-07-02T16:35:28.119Z","phase":"Phase 2","brief_title":"A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma","source_id_and_acronym":"NCT04629209","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification • EGFR expression • EGFRvIII expression • EGFR underexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • EGFR expression • EGFRvIII expression • EGFR underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/28/2024","start_date":" 06/28/2024","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-11-24"},{"id":"4012ef46-eb93-4087-876c-82a648c0d4c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05400915","created_at":"2022-06-02T16:58:54.112Z","updated_at":"2024-07-02T16:35:29.638Z","phase":"Phase 1/2","brief_title":"Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients","source_id_and_acronym":"NCT05400915","lead_sponsor":"Yonsei University","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 amplification • HER-2 expression • EGFR amplification • EGFR expression","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 amplification • HER-2 expression • EGFR amplification • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • varlitinib (ASLAN001)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 07/23/2019","start_date":" 07/23/2019","primary_txt":" Primary completion: 12/13/2021","primary_completion_date":" 12/13/2021","study_txt":" Completion: 06/13/2022","study_completion_date":" 06/13/2022","last_update_posted":"2023-11-10"},{"id":"ee75280d-fc90-465e-b0a5-f0b3469013da","acronym":"","url":"https://clinicaltrials.gov/study/NCT05176665","created_at":"2022-01-04T13:53:37.122Z","updated_at":"2024-07-02T16:35:35.271Z","phase":"Phase 1/2","brief_title":"EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers","source_id_and_acronym":"NCT05176665","lead_sponsor":"Shanghai EpimAb Biotherapeutics Co., Ltd.","biomarkers":" EGFR • KRAS • BRAF • ALK • NRAS • ROS1 • FGFR • NTRK","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • MET amplification • EGFR amplification • EGFR overexpression","tags":["EGFR • KRAS • BRAF • ALK • NRAS • ROS1 • FGFR • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • MET amplification • EGFR amplification • EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bafisontamab (EMB-01)"],"overall_status":"Recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 08/04/2024","primary_completion_date":" 08/04/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2023-09-29"},{"id":"5bec0696-6933-431c-a87d-bd8f954d4389","acronym":"","url":"https://clinicaltrials.gov/study/NCT06022276","created_at":"2023-09-01T17:11:46.994Z","updated_at":"2024-07-02T16:35:38.278Z","phase":"","brief_title":"Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors","source_id_and_acronym":"NCT06022276","lead_sponsor":"Tianjin Medical University Second Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification • CDKN2A negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TheraCIM (nimotuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-09-01"},{"id":"b5eabf3e-d6e6-4d57-852d-3eacbb090310","acronym":"MIRROR","url":"https://clinicaltrials.gov/study/NCT05929456","created_at":"2023-07-03T16:10:45.950Z","updated_at":"2024-07-02T16:35:44.164Z","phase":"Phase 1","brief_title":"Multispectral Bimodal Fluorescence Guided Surgery of High-grade Glioma With Cetuximab-800CW and 5-ALA (5-aminolevulinic Acid)","source_id_and_acronym":"NCT05929456 - MIRROR","lead_sponsor":"University Medical Center Groningen","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 05/05/2023","start_date":" 05/05/2023","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-07-03"},{"id":"1e7d842e-e4ca-4d95-b896-1da6f52d2d98","acronym":"","url":"https://clinicaltrials.gov/study/NCT03726515","created_at":"2021-01-18T18:15:36.195Z","updated_at":"2024-07-02T16:35:44.942Z","phase":"Phase 1","brief_title":"CART-EGFRvIII + Pembrolizumab in GBM","source_id_and_acronym":"NCT03726515","lead_sponsor":"University of Pennsylvania","biomarkers":" EGFR • MGMT • TERT","pipe":" | ","alterations":" EGFR amplification • MGMT promoter methylation • TERT mutation • EGFRvIII expression • IDH wild-type • TERT promoter mutation","tags":["EGFR • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • MGMT promoter methylation • TERT mutation • EGFRvIII expression • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • LXF821"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 03/11/2019","start_date":" 03/11/2019","primary_txt":" Primary completion: 02/27/2021","primary_completion_date":" 02/27/2021","study_txt":" Completion: 02/27/2021","study_completion_date":" 02/27/2021","last_update_posted":"2023-06-22"},{"id":"6f24da17-d18e-4f79-befe-3764e25c2b19","acronym":"","url":"https://clinicaltrials.gov/study/NCT05271240","created_at":"2022-03-08T16:52:43.604Z","updated_at":"2024-07-02T16:35:47.014Z","phase":"Phase 3","brief_title":"Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM","source_id_and_acronym":"NCT05271240","lead_sponsor":"Northwell Health","biomarkers":" EGFR • TERT","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["EGFR • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 432","initiation":"Initiation: 04/27/2022","start_date":" 04/27/2022","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2023-05-29"},{"id":"8a12a2b1-4461-4e08-a123-bacd09514bb9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03618667","created_at":"2021-01-18T17:46:59.647Z","updated_at":"2024-07-02T16:35:48.108Z","phase":"Phase 2","brief_title":"GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification","source_id_and_acronym":"NCT03618667","lead_sponsor":"Samsung Medical Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GC-1118A"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 01/22/2018","start_date":" 01/22/2018","primary_txt":" Primary completion: 09/08/2018","primary_completion_date":" 09/08/2018","study_txt":" Completion: 04/28/2022","study_completion_date":" 04/28/2022","last_update_posted":"2023-05-12"}]